The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. It’s like taking out the trash.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

pharmaphorum

AUGUST 11, 2022

The program is aiming to genotype roughly 150,000 participants over the next few years to demonstrate the impact personalised testing can have on a large scale. In the near future, more testing must be put into place and standardised throughout the industry. The post How Pharmacogenomics may finally realise its promise appeared first on.

Genome 98

Genome Genomics Genetics Drugs 98

pharmaphorum

NOVEMBER 10, 2021

This database should support automatic importation from hospitals, laboratories and surveillance networks and link to genotypic data when available.”. The medicines needed to treat resistant infections are complicated to develop and have a relatively small market both in terms of duration of use, usually only a few days, and need,” it said.

Medicine 106

Medicine Genome Genomics Genotype 106

XTalks

APRIL 24, 2023

Dr. Eagleton recently spoke on a webinar with his colleagues from Medpace about lessons learned from successful approaches from rare disease and gene therapy product approvals. Last year, the FDA approved five novel cellular and gene therapy products with orphan drug designation. How Can Study Protocols Be More Effective?

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

Drug Discovery World

NOVEMBER 23, 2023

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. Research that once took months to complete – requiring synthesizing and testing compounds – can now be done in days and even hours using AI.

Biobanking 59

Biobanking Drugs Medicine Genome 59

The Pharma Data

MARCH 16, 2022

3, and Delta ([link] About TIB Molbiol TIB Molbiol is a subsidiary of Roche Diagnostics that has supplied the global market with reagents for research and medical diagnostics for over 30 years. To support customers performing human genotyping, TIB Molbiol provides custom-made LightSNiP assays for SNP analysis.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

Pharmaceutical Technology

AUGUST 18, 2022

0 genotypes. A genetic blood ailment, beta-thalassemia is caused by beta-globin gene mutations and results in a substantial decline or lack of production of adult haemoglobin. In June 2019, the European Commission (EC) granted conditional marketing authorisation for Zynteglo to treat transfusion-dependent beta-thalassemia.

Gene Therapy 246

Gene Therapy Gene Genotype Genetics 246

Delveinsight

AUGUST 25, 2021

They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing. . The company offers a variety of products under the three major business divisions i.e. Pharmaceutical, Medical Devices, and Consumer Health. The global healthcare spending in 2020 was USD 8.3 trillion in 2021.

Vaccination 98

Vaccination Vaccine Sales Drugs 98

The Pharma Data

MARCH 25, 2021

The MAA is now under accelerated review by the EMA, in recognition of the product being considered of major interest for public health and therapeutic innovation. The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

pharmaphorum

DECEMBER 9, 2020

bluebird bio has presented long-term data from its Zinteglo one-time gene therapy for the blood disorder beta-thalassaemia, as the company continues talks with payers in Europe to bring the ultra-pricey treatment to market. In Europe bluebird has set a price of up to $1.58 million euros for a single shot.

Gene Therapy 59

Gene Therapy Gene Genotype Marketing 59

Roots Analysis

SEPTEMBER 20, 2023

Cannabis-infused products primarily contain the cannabinoids cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). THC is main psychoactive cannabinoid, which is used in recreational products. The market for cannabis-infused products is growing like weed. Which Countries have Legalized the Use of Medical Cannabis?

Laboratory Information Management System 40

Laboratory Information Management System Production Contamination Containment 40

The Pharma Data

NOVEMBER 24, 2020

The excess production of oxalate results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones, nephrocalcinosis, progression to kidney failure, and systemic organ dysfunction. President of R&D at Alnylam.

FDA Approval 52

FDA Approval Production RNA Medicine 52

Roots Analysis

AUGUST 31, 2023

Similarly, people suffering from lactose intolerance must avoid milk products. Considering the growing popularity and awareness related to personalized nutrition, a number of players may join the market with the aim to make financial profit. Figure below presents an overview of nutrigenomics.

Genome 40

Genome Genomics Genetics Gene 40

XTalks

DECEMBER 12, 2023

The worldwide market for neurology clinical trials stood at a valuation of $5.24 It aids in optimizing individualized treatment plans by offering insights into brain volume to help inform the selection of the precise dose of the investigational product (IP). billion in 2022. percent between 2023 and 2030.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

The Pharma Data

APRIL 7, 2021

The European Medicines Agency has also validated a Marketing Authorization Application for Trodelvy in the European Union. The incidence of Grade 3-4 neutropenia in genotyped patients was 69% in patients homozygous for the UGT1A1*28, 48% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele.

HR 52

HR Genotype FDA Approval Genotoxicity 52